Global Proteomics Market - 2023-2030
The global proteomics market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030 growing with a CAGR of XX% during the forecast period 2023-2030.
The proteomics market trends show rising research owing to the rising technological advancements and research studies. Furthermore, rising application for proteomics due to the rising availability of approved instruments and increase in the number of cancer cases in the market, and an increase in the research and development is driving up the proteomics market size.
The market is experiencing a growth in demand for treatment from North America as a result of the rising advancements in this field. With significant competitors like Thermo Fisher Scientific Inc., Danaher, Agilent Technologies, Inc., and Merck KGaA actively operating in the market, the market will grow in upcoming time.
The Growing Number of Research on Biomarkers Usage for Cancer Drive the Growth of the Proteomics Market
Proteomics technology is currently widely applied in molecular medicine, particularly for the identification of biomarkers. Proteomics can find significant disease-specific biomarkers by evaluating a global protein profiling in bodily fluids. By contrasting the protein expression profiles of healthy samples with those affected by disease, expression of proteomics enables the identification of biomarkers. The simplest method for finding biomarkers is 2D-PAGE, in which the protein profiles of healthy and sick samples, including tumor tissues and bodily fluids, are compared.
According to the information they provide, disease-specific biomarkers can be classified as prognostic, diagnostic, and treatment-predictive biomarkers. Proteins that may act as disease-associated biomarkers or be implicated in the course of disease can be found using proteomics. After being discovered by mass spectrometry, biomarkers need to be processed using bioinformatics analysis and replicated in other populations.
Unfortunately, only a few of the biomarkers revealed utilizing proteomics technology were ultimately validated and authorized by the FDA for use in clinical settings despite the increased interest, heavy investigational burdens, and a substantial level of publications. The market is predicted to take the lead throughout the forecast period owing to high research studies.
Rising Collaboration by Key Players or Several Organizations Creates Opportunities for the Growth of the Market
As a result of years of study, a number of major manufacturers or organizations are now developing or studying several products for their usage in proteomics to gain more knowledge and treat several diseases, which is promoting the expansion of the proteomics market. Researchers looking into proteomics for innovative drug discovery have a big opportunity due to the growth and development of the field by important stakeholders through partnerships or collaborations. Proteomics workflows, for instance, have been enhanced in terms of throughput, completeness, and quality for applications like single-cell studies in addition to translational research.
According to a November 2021 announcement from Thermo Fisher Scientific Inc., Thermo Fisher recently renewed their collaborative marketing contract with Biognosys, an innovator of next-generation proteomics solutions, in order to provide laboratories executing high-throughput plasma studies with cutting-edge or streamlined kits, instruments, and software for developing precise and effective workflows at scale. Such research collaborations may help in providing better treatments via high study on proteomics.
The High Cost and Limitations Associated with Proteomic Technology will hamper the growth of the market
The evaluation's complexity, the inconsistent way samples are processed, the potential for significant false positives, the sample's variability restricting the low protein abundance calculation, the analysis software's propriety making it unavailable, the difficulty in determining the threshold between signal and noise, the lack of rigorous statistical application, protein hindrance ignorance, and signal suppression.
Proteomics in biomarker also has its limitations and it should be mentioned that patient heterogeneity is one of the main obstacles to biomarker identification, particularly in cancer. The vast dynamic variety of plasma proteins, limited abundance of important biomarkers in plasma, or patient variability provide difficulties for biomarker identification utilizing plasma proteomics. Despite the development of proteomic techniques, the current one method cannot yet simultaneously overcome the aforementioned difficulties in the process of finding new biomarkers in the plasma proteome. These elements can limit the market's expansion.Segment Analysis
The global proteomics market is segmented based instrumentation technology, application, services and software, end user and region.
Owing to High Research, the Drug Discovery from Application Segment Accounted for Approximately 56.1% of the Proteomics Market Share
The drug discovery category from application held the largest market share in 2022 and is expected to maintain its dominance over the forecast period due to a growth in proteomics worldwide. Proteomics research based on MS has increased its influence during the past several years across practically all scientific disciplines. Because finding new drugs is a costly and complex process, newer technologies like proteomics can help and speed up the discovery process. Each new medicine candidate's discovery is thought to cost $70 million.
Drug development involves multiple stages and is a multidisciplinary field that makes use of system biology, genetics, proteomics, and metabolomics. Proteomics is important in the target identification phase. Studies on proteomics are helpful for examining medication activity, toxicity, resistance, and efficacy. Proteomics-based methodologies are more favorable than genomics, despite the fact that genomics is particularly useful in the drug development process, for a number of reasons.
The transcriptome stage is the only one to which genomics can convey biological events, and gene expression profiles are not indicative of protein expression. Therefore, the majority of research focuses on proteomics studies that quantitatively assess proteins and associated post-translational modifications (PTMs).
North America Accounted for Approximately 37.5% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment
Due to the rising need for proteomics in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for application for proteomics.
Increasing expenditure on healthcare and rising research studies, advancement of technologies for treatment of diseases, and increase in pharmaceutical and biotechnology business establishment across the region are also contributing to the growth of proteomics market share of this region.
It is also anticipated that the main healthcare organizations' and enterprises' collaborative research projects as well as new product development, which constantly seeks to improve available alternatives, will contribute to the expanding demand. Individuals are becoming more aware of various instrumentation technologies and application for proteomics that are being utilized for management purposes, leading to the expansion of the market in this region. The above-mentioned factors further proves the dominance of North America on a global scale.Competitive Landscape
The major global players in the proteomics market include Thermo Fisher Scientific Inc., Danaher, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Bruker, Merck KGaA, Promega Corporation, Waters Corporation, PerkinElmer Inc. and Panacea Biotec among others.COVID-19 Impact Analysis
Russia Ukraine Conflict Analysis
Due to the low prevalence as well as absence of major market participants in this region, it is predicted that the Russia-Ukraine conflict will not have a significant effect on the worldwide proteomics market. The growth of the global proteomics market, however, is anticipated to be relatively unaffected by the import and export of raw materials over the forecast period.
By Instrumentation Technology
Supercritical Fluid Chromatography
• Protein Microarrays
• X-Ray Crystallography
• Surface Plasmon Resonance
• Protein Fractionation
• Drug Discovery
• Clinical Diagnostics
By Services and Software
• Bioinformatics Software and Services
• Core Proteomics Services
Protein Identification Services
Protein Characterization Services
Quantitative Proteomics Services
Protein Purification Services
Protein Separation Services
Protein Sequencing Services
Custom Assay Services
By End User
• Research Laboratories
• Biopharmaceutical Companies
• North America
Rest of Europe
• South America
Rest of South America
Rest of Asia-Pacific
• Middle East and AfricaKey Developments
• On June 5, 2023, in conjunction with the introduction of the new timsTOF Ultra mass spectrometer, Bruker Corporation announced transformational sensitivity on its 4D-Proteomics timsTOF platform. It has a brand-new 4th-generation trapped ion mobility separation XR cell, a 14bit digitizer, a new Captive Spray Ionization (CSI) Ultra ion source with a bigger capillary and improved vortex gas flow.
• On March 7, 2023, proteomics or biopharmaceutical research facilities can now use the latest generation of low-flow HPLC columns from Thermo Fisher Scientific to enhance the separation efficiency and durability of biologically complicated samples. The PAC Neo low-load trapping column, the newest addition to the portfolio, is perfect for the lowest sample sizes in single-cell proteomics separations and has built-in nanoViper connections with Vanquish Neo UHPLC equipment for simplicity of use and decreased chance of errors.
• On February 17, 2022, Agilent Technologies Inc. acquired cutting-edge artificial intelligence (AI) technology created by Virtual Control, a maker of AI and machine learning software that develops novel analysis methods for laboratory testing. The software, dubbed ACIES, will be incorporated by Agilent into its top-tier gas chromatography with mass spectrometry platforms in order to boost the effectiveness, efficiency, and precision of the high-throughput labs that the business works with all over the world.
The global proteomics market is going to see decent growth in upcoming years owing to rising usage of proteomics and novel instruments/product launches. Several researches are taking place worldwide for treatment of cancer. Numerous advances are taking place leading to the growth of market such as biomarkers. According to DMI the proteomics market will see a decent growth with several novel treatments in the market.Why Purchase the Report?
• To visualize the global proteomics market segmentation based on instrumentation technology, application, services and software, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of proteomics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global proteomics market report would provide approximately 53 tables, 54 figures and 195 Pages.Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies